Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study

M Pérez; I Tůma; O Pytela; E Kadlecová; M Zemanová; Z Lenderová

doi:10.1016/j.eurpsy.2006.04.008

Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study

Eur Psychiatry. 2006 Dec;21(8):548-50. doi: 10.1016/j.eurpsy.2006.04.008. Epub 2006 Jun 23.

Authors

M Pérez¹, I Tůma, O Pytela, E Kadlecová, M Zemanová, Z Lenderová

Affiliation

¹ Department of Psychiatry, Hospital Havirov, Charles University, Prague, Faculty of Medicine, Hradec Kralove, Czech Republic. prim.psychiatrie@nsphav.cz

PMID: 16797936
DOI: 10.1016/j.eurpsy.2006.04.008

Abstract

The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia. It focuses on an analysis of a sub-group of 20 patients receiving treatment of the donepezil in an extended Czech double-blind placebo controlled study.

Publication types

Controlled Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Cholinesterase Inhibitors / therapeutic use*
Cognition Disorders / complications
Cognition Disorders / drug therapy*
Cognition Disorders / psychology
Czech Republic
Donepezil
Double-Blind Method
Female
Humans
Indans / therapeutic use*
Male
Memory / drug effects
Middle Aged
Neuropsychological Tests
Piperidines / therapeutic use*
Schizophrenia / complications
Schizophrenia / drug therapy*
Schizophrenic Psychology
Treatment Outcome

Substances

Cholinesterase Inhibitors
Indans
Piperidines
Donepezil